Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

NCT04037462 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

FED

Sponsor class

Stopped Low accrual

Conditions

Non-Small Cell Lung Cancer
Immunotherapy

Interventions

DRUG: Dexamthasone

Sponsor

VA Office of Research and Development

Collaborators

[object Object]
[object Object]
[object Object]